InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital began coverage on InspireMD in a report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price target for the company.

InspireMD Stock Performance

Shares of NYSE NSPR opened at $2.76 on Tuesday. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.42. The business’s 50-day simple moving average is $2.82 and its 200-day simple moving average is $2.72. The firm has a market cap of $71.98 million, a price-to-earnings ratio of -3.68 and a beta of 0.99.

InspireMD (NYSE:NSPR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The business had revenue of $1.81 million for the quarter, compared to analyst estimates of $1.74 million. During the same period in the previous year, the company posted ($0.15) earnings per share. As a group, equities research analysts forecast that InspireMD will post -0.79 earnings per share for the current year.

Hedge Funds Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Parkman Healthcare Partners LLC bought a new position in shares of InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned about 0.42% of InspireMD as of its most recent SEC filing. 44.78% of the stock is owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.